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Synopsis:  18 
Objectives: Effective skin antisepsis and disinfection of medical devices are key factors 19 
in preventing many healthcare acquired infections associated with skin microorganisms, 20 
particularly, Staphylococcus epidermidis. The aim of this study was to investigate the 21 
antimicrobial efficacy of chlorhexidine digluconate (CHG), a widely used antiseptic in 22 
clinical practice, alone and in combination with tea tree oil (TTO), eucalyptus oil (EO) 23 
and thymol against planktonic and biofilm cultures of S. epidermidis.  24 
Methods: Antimicrobial susceptibility assays against S.epidermidis in a suspension and in 25 
a biofilm mode of growth were performed with broth microdilution and ATP 26 
bioluminescence methods respectively. Synergy of antimicrobial agents was evaluated 27 
with checkerboard assay.  28 
Results: Chlorhexidine exhibited antimicrobial activity against S. epidermidis in both 29 
suspension and biofilm [Minimum inhibitory concentration (MIC) 2–8 mg/ L]. Of the 30 
essential oils thymol exhibited the greatest antimicrobial efficacy (MIC 0.5–4 g/ L) 31 
against S. epidermidis in suspension and biofilm followed by TTO (MIC 2–16 g/ L) and 32 
EO (4–64 g/ L).  Minimum inhibitory concentrations of CHG and EO were reduced 33 
against S. epidermidis biofilm when in combination (MIC 8 reduced to 0.25-1 mg/ L and 34 
32-64 reduced to 4 g/L for CHG and EO respectively). Furthermore, the combination of 35 
EO with CHG demonstrated synergistic activity against S. epidermidis biofilm with a 36 
fractional inhibitory concentration index (FICI) of <0.5.  37 
Conclusion: The results from this study suggest there may be a role for essential oils, in 38 
particular EO, for improved skin antisepsis when combined with CHG. 39 
Introduction: Incision of human skin is a common practice in the clinical setting, for 40 
example during surgery, when taking blood or inserting intravascular devices.  Adequate 41 
skin antisepsis is therefore essential in avoidance of healthcare associated infections 42 
(HAI) which may occur post incision, commonly from resident microorganisms located 43 
within the skin, particularly S. epidermidis.
1, 2
 Staphylococcus epidermidis is common on 44 
both the surface of human skin and also within the deeper layers where it may exist as 45 
microcolonies, which, like bacterial biofilms, exhibit increased resistance to 46 
antimicrobials including antiseptics.
3
 Unfortunately, HAI do arise following incision of 47 
skin
4,5
 and are likely to be associated with increased prevalence of microbial resistance to 48 
antibiotics and antiseptics and inadequate skin antisepsis which encompasses both the 49 
contact time between skin and antiseptic prior to incision and permeation of the antiseptic 50 
within the skin.
6-10
 Chlorhexidine is one of the most widely used antimicrobials within 51 
clinical practice for skin antisepsis and is currently recommended within the Evidence-52 
Based Practice in Infection control (EPIC)
11
 and Healthcare Infection Control Practices 53 
Advisory Committee (HICPAC)
12
 guidelines. However, its antimicrobial efficacy is 54 
significantly reduced by factors including pH and organic matter.
13 
Therefore additional 55 
strategies for skin antisepsis or improvement of existing methods need to be considered. 56 
The antimicrobial efficacy of essential oils has been known for several years and 57 
many studies have demonstrated activity against bacteria, fungi and viruses.
14
 More 58 
recently, in the light of increased antimicrobial resistance within the clinical setting, the 59 
potential of essential oils for the prevention and treatment of infection has been 60 
researched in several studies.
15-19  
Indeed, TTO has recently been shown to be more 61 
effective than CHG at clearing superficial skin sites and lesions colonised with 62 
methicillin resistant S. aureus.
17 
In addition, preliminary research within our laboratory 63 
has demonstrated that several essential oils (EO, TTO, thymol, lavender, juniper and 64 
citronella) have antimicrobial efficacy against a wide range of microorganisms associated 65 
with HAI.
20
 Many of the essential oils are thought to disrupt cell membranes by the 66 
lipophilic compounds contained within the essential oil, such as terpenes. However, 67 
essential oils are mixtures of many heterogeneous compounds, and the main components 68 
responsible for their antimicrobial activity and the mode of their activity are not well 69 
understood.
14
 Furthermore, essential oils have been shown to act as effective penetration 70 
enhancers, increasing permeation and improving retention of drugs within the skin.
21,22
 71 
The aim of this study was to investigate the antimicrobial efficacy of aqueous 72 
CHG alone and in combination with TTO, EO and thymol against planktonic and biofilm 73 
cultures of S. epidermidis. 74 
75 
Materials and methods 76 
 77 
Materials 78 
Congo red agar for demonstrating slime production in the test strain S.epidermidis was 79 
prepared by mixing 0.4 g of Congo red (Hopkins and Williams Ltd, Essex, UK), 25 g 80 
sucrose (Fisher Scientific, Leics, UK) and 5 g of agar No.1 (Oxoid, Basingstoke, UK) 81 
with 490 mL of brain heart infusion (BHI) (Oxoid) and sterilised according to the 82 
manufacturers’ recommendations. Mueller-Hinton agar (MHA) and Mueller-Hinton broth 83 
(MHB) (Oxoid) were also prepared and sterilised in line with the manufacturers’ 84 
recommendations. Phosphate buffered saline (PBS), aqueous CHG (20% in water), TTO 85 
(40.2% terpinen-4-ol and 3.5% cineole), EO (82.9% cineole), thymol (>99.5%) and 86 
dimethylsulphoxide (DMSO) were purchased from Sigma-Aldrich (Dorset, UK) and 87 
glucose from Fisher Scientific. White walled, clear bottom, tissue culture treated 96-well 88 
microtitre plate were from Corning Incorporated (NY, USA) and clear, round bottom 96-89 
well plates from Barloworld Scientific (Staffordshire, UK). 90 
 91 
Microorganisms 92 
Staphylococcus epidermidis RP62A 
23
 and a clinical isolate of S.epidermidis, TK1, 93 
(University Hospital Birmingham NHS Trust, Birmingham, UK) were stored on 94 
MicroBank beads (Pro-Lab Diagnostics, Cheshire, UK) at -70˚C until required.  95 
 96 
97 
Preparation of antimicrobial agents 98 
Aqueous CHG was diluted with MHB to obtain a stock solution of 512 mg/ L. Thymol, 99 
TTO and EO were diluted with MHB to obtain stock solutions of 512 g/ L. Five percent 100 
(v/v) DMSO was added to the essential oil stock solutions to enhance the solubility of the 101 
oils in solution. 102 
 103 
Preparation of S.epidermidis inoculum for suspension assay 104 
Suspensions of S.epidermidis for the suspension assays were prepared by inoculating 10 105 
identical colonies of overnight cultures of S.epidermidis from MHA into sterile PBS. The 106 
bacterial concentration was adjusted to 1 x 10
8
 cfu/ mL by diluting the culture with sterile 107 
PBS and measuring the optical density at 570 nm. The suspensions were further diluted 108 
with MHB to obtain inocula containing 1x10
6
 cfu/ mL. 109 
 110 
Determination of MIC and MBC of CHG, TTO, EO and thymol against S.epidermidis in 111 
suspension 112 
Minimum inhibitory concentration of aqueous CHG and TTO, EO and thymol were 113 
determined using a broth microdilution assay in line with CLSI (formerly NCCLS) 114 
guidelines.
24
 The antimicrobial activity of 5 % (v/v) DMSO was also studied on a 115 
separate microtitre plate alongside the assay. Each well containing 100 µL of 116 
antimicrobial agent was inoculated with 100 µL of S.epidermidis suspension containing 117 
1x10
6
 cfu/ mL. Following 24 h incubation in air at 37˚C, the wells were inspected for 118 
microbial growth and the MIC was defined as the lowest concentration which did not 119 
show visual growth. Controls containing antimicrobial agent in broth and broth with 120 
inocula were also included. Minimum bactericidal concentrations were determined by 121 
removing the total volume (200 µL) from each of the clear wells and mixing with 20 mL 122 
of cooled molten MHA, which was then allowed to set. Plates were incubated in air at 37˚ 123 
C for 24 h. Minimum bactericidal concentration was defined as the first plate yielding no 124 
growth. The assay was performed in triplicate. 125 
 126 
Checkerboard assay to assess antimicrobial activity of CHG in combination with TTO, 127 
EO and thymol against S.epidermidis in suspension 128 
The antimicrobial activity of aqueous CHG in combination with TTO, EO and thymol 129 
was assessed in a suspension assay by the checkerboard method.
25
 In brief, serial double-130 
dilutions of the antimicrobial compounds were prepared (256 to 1 g/L for EO and TTO, 131 
64 to 0.25 g/ L for thymol and 64 to 0.5 mg/L for CHG). Fifty microlitres of each CHG 132 
solution was added to the rows of a 96-well microtitre plate in diminishing concentrations 133 
and 50 μL of the essential oil to the columns in diminishing concentrations. The wells 134 
were then inoculated with 100 μL of S.epidermidis suspension containing 1x105 cfu (the 135 
final concentrations of EO and TTO ranged from 64 to 0.25 g/L, thymol 16 to 0.06 g/L 136 
and CHG 16 to 0.125 mg/L). Columns 10, 11 and 12 served as controls containing MHB 137 
and inoculum alone, and antimicrobial compounds separately with the inoculum. The 138 
microtitre plates were incubated in air at 37˚ C for 24 h and MIC for both antimicrobial 139 
compounds in combination was determined. To assess synergistic or antagonistic activity 140 
of antimicrobial combinations, the fractional inhibitory concentration (FIC) and FIC 141 
index (FICI) were determined using the following formulae: 142 
 143 
FIC= MIC of CHG or natural compound in combination 144 
MIC of CHG or natural compound alone 145 
 146 
FICI=  FIC of oil + FIC of CHG 147 
 148 
FICI ≤ 0.5 were regarded as synergistic effect, values between 0.5 to 4.0 as 149 
indifferent and over 4.0 as antagonistic activity. The assay was performed in 150 
duplicate microtitre plates. 151 
 152 
Preparation of S.epidermidis biofilm 153 
The ability of S.epidermidis strains to produce slime was confirmed by culturing the 154 
bacteria on Congo red agar.
26
 The optimal conditions and incubation period for the 155 
production of the bacterial biofilms were established in preliminary experiments over a 156 
72 h period (data not shown). Bacterial biofilms were prepared by aliquoting 200 µL of 157 
the bacterial suspension containing 1x10
5
 cfu/ mL into the wells of white walled, clear 158 
bottom, tissue culture treated 96-well microtitre plates. Four wells in the last column of 159 
each plate were left blank to serve as bioluminescence negative control. Suspensions of 160 
S.epidermidis were prepared in MHB supplemented with 2% (w/v) glucose. Microtitre 161 
plates containing S.epidermidis suspensions were incubated in air at 37˚ C for 48 h (these 162 
conditions demonstrated in preliminary experiments to be optimal conditions for 163 
production of a confluent biofilm with approximately 5.5x10
6
 cfu per well - data not 164 
shown). 165 
 166 
Determination of MIC and MBC of CHG, TTO, EO and thymol against S.epidermidis in 167 
biofilm 168 
Microtitre plates containing S.epidermidis biofilms were washed once with sterile PBS to 169 
remove any unbound bacteria. Antimicrobial agents were diluted with MHB to obtain 170 
CHG concentrations ranging from 128 mg/ L to 0.25 mg/ L, thymol 128 to 0.25 g/L and 171 
EO and TTO 256 to 0.5 g/L. Two hundred and fifty microlitres of each antimicrobial 172 
agent was added to each microtitre plate well. Columns 11 and 12 served as controls 173 
containing the biofilm and saline alone and MHB alone without bacterial biofilm. 174 
Antimicrobial activity of 5% (v/v) DMSO against the bacterial biofilm was also tested on 175 
a separate plate. Following incubation at 37˚C in air for 24 h, the wells were washed once 176 
with sterile PBS and the microbial viability was determined using an ATP 177 
bioluminescence assay (ViaLight MDA Bioassay kit, Cambrex, Berkshire, UK). In brief, 178 
100 µL of Bactolyse was added with 100 µL of saline into each well and the plates 179 
sonicated at 50 Hz for 30 min to release and lyse the cells of the bacterial biofilm. Fifty 180 
microlitres of ATP-monitoring reagent was added to each well and luminescence 181 
measured (Lucy 1, type 16 850 fluorescence measurer, Rosys Anthos Labtech 182 
Instruments). Minimum inhibitory concentration was defined as the minimum 183 
concentration of antimicrobial agent that inhibited further growth of the initial biofilm 184 
(control well containing biofilm treated with saline) and MBC was defined as the 185 
concentration that produced below or equal to the background level of luminescence 186 
(empty well). The assay was performed in duplicate microtitre plates. 187 
 188 
Checkerboard assay to assess antimicrobial activity of CHG in combination with TTO, 189 
EO and thymol against S.epidermidis in biofilm 190 
Microtitre plates containing S.epidermidis biofilms were washed once with sterile PBS to 191 
remove any unbound bacteria. Antimicrobial agents were diluted with MHB as described 192 
previously and 125 µL of each of the antimicrobial dilutions aliquoted into each well in 193 
decreasing concentrations. Columns 10 and 11 contained biofilm and antimicrobial 194 
compounds alone at various concentrations and column 12 served as control with biofilm 195 
with saline and clear wells with saline. The plates were incubated in air at 37˚C for 24 h 196 
after which the wells were emptied and the FIC and FICI values determined by ATP 197 
bioluminescence as described previously. The assay was performed in duplicate. 198 
 199 
Results 200 
 201 
Determination of MIC and MBC of CHG, TTO, EO and thymol against S.epidermidis in 202 
suspension and in biofilm 203 
Chlorhexidine digluconate, TTO, EO and thymol demonstrated antimicrobial activity 204 
against S.epidermidis RP62A and S.epidermidis TK1 in both suspensions and biofilms 205 
(Table 1). Minimum inhibitory concentration and MBC of CHG were 4-fold higher 206 
against S.epidermidis growing in biofilm compared to cells in suspension (MIC 2 to 8 207 
mg/ L and MBC 4 to 16 mg/ L). Of the three essential oils thymol was the most effective 208 
with MIC ranging from 0.5 to 4 g/ L and MBC 2 to 16 g/ L. All antimicrobials tested 209 
reduced the luminescence from the bacterial biofilms to below negligible levels with 210 
concentrations of 16 mg/ L (CHG), 2-8 g/ L (thymol), 32-64 g/ L (TTO) and 256 g/ L 211 
(EO). Five percent (v/v) DMSO, which was used as co-solvent in oil solutions, did not 212 
show antimicrobial activity against S.epidermidis in biofilm or suspension. 213 
 214 
Checkerboard assay to assess antimicrobial activity of CHG in combination with TTO, 215 
EO and thymol against S.epidermidis in suspension and in biofilm 216 
Combination of CHG with TTO, EO and thymol demonstrated indifferent activity against 217 
S.epidermidis RP62A and TK1 when grown in suspension (Table 2). In biofilm, CHG in 218 
combination with EO demonstrated synergistic activity against both strains of 219 
S.epidermidis, with FICI of 0.156 and 0.188 for S.epidermidis RP62A and TK1 220 
respectively (Table 3). 221 
 222 
Discussion:  223 
 224 
The aim of this study was to assess the antimicrobial efficacy of aqueous CHG and three 225 
essential oils (TTO, EO and thymol) against the common skin microorganism, 226 
S.epidermidis, and to determine the antimicrobial activity of CHG in combination with 227 
the oils. 228 
The results demonstrate that CHG, EO, TTO and thymol exhibit antimicrobial 229 
activity against S.epidermidis when growing both in suspension and as a biofilm. 230 
However, the concentration of essential oils required to achieve the same level of growth 231 
inhibition as CHG is several orders of magnitude higher (g/ L for essential oils compared 232 
to mg/ L for CHG). Thymol showed increased activity against S.epidermidis growing in 233 
biofilm compared with planktonic cells. This is unusual as biofilms are considered to be 234 
more resistant to antimicrobial agents compared to planktonic cells.
3
 Partitioning of oil, 235 
especially pure compound thymol, in oil suspension as well as in extracellular matrix in 236 
bacterial biofilm, may alter thymol activity. In a previous study by Nostro et al.,
27
 only 237 
small differences between biofilm and planktonic cultures susceptibility to thymol was 238 
demonstrated. Furthermore, in the study by Al-Shuneigat et al.,
15
 staphylococci in a 239 
biofilm mode of growth demonstrated increased susceptibility to an essential oil based 240 
formulation compared with planktonic cells, which concurs with our findings in relation 241 
to thymol. Thymol is a phenolic compound that has both hydrophilic and hydrophobic 242 
properties which may enhance diffusion of this compound in a biofilm and allow its 243 
access to bacterial cells where it alters the permeability of plasma membranes.
27
 244 
Combining CHG with TTO, EO and thymol did not improve its antimicrobial 245 
activity against S.epidermidis TK1 and RP62A strains during their planktonic phase of 246 
growth, however, reductions in CHG concentrations required to inhibit growth of both 247 
S.epidermidis strains in biofilm were observed. Of the three essential oils used in this 248 
investigation, EO demonstrated the best potential for combination with CHG.  Synergistic 249 
activity between EO and CHG was demonstrated against biofilms of both strains of S. 250 
epidermidis (FICI 0.19 and 0.16 for TK1 and RP62A respectively). To our knowledge, 251 
this is the first report of synergism between EO and CHG. 252 
Previous research that has investigated the synergistic activity of an essential oil 253 
and an antimicrobial agent has suggested that the synergism may be due to their action on 254 
both different
28
 or similar targets on the bacterial cell (i.e. cell membranes).
29
 Eucalyptus 255 
oil and its main component 1,8-cineole are thought to act on the plasma membranes, the 256 
same target as CHG. However, TTO (and its main antimicrobial component terpinen-4-257 
ol) and thymol also have lipophilic properties and target cellular membranes without 258 
showing synergy in combination with CHG. Therefore, the interaction of EO and CHG 259 
requires further studies to establish the mode of action of the potential synergism. It is 260 
possible that not only one component is involved in the synergistic interaction between 261 
EO and CHG, but a mixture of several components. Moreover, it has been suggested that 262 
cationic CHG diffusion in the biofilm is hindered by the negatively charged extracellular 263 
matrix, changing the physicochemical properties of the extracellular matrix and its 264 
tertiary structure.
30
 Chlorhexidine is likely to remain in the aqueous phase in the oil 265 
suspension (Log P of CHG 0.037 
31
). Both EO, which consists of several heterogeneous 266 
compounds, and CHG have hydrophilic and hydrophobic properties, and it may be 267 
possible that they alter ionic interactions in extracellular matrix of the biofilm, as well as 268 
act on the same target on the bacterial cell. However, further studies are needed to 269 
establish the mode of action of EO and CHG in combination. 270 
The use of essential oils for the prevention and treatment of infection has been 271 
gaining popularity within the research field over the past decade.
19,32-34
 Furthermore, the 272 
antimicrobial activity of TTO 
16,17
, thymol 
27
 and EO 
35
 has been reported against several 273 
important pathogens.  However, there has been little research to assess the efficacy of 274 
essential oils in combination with CHG against S. epidermidis, which is the major 275 
microorganism associated with skin related HAI. Chlorhexidine is widely used as a skin 276 
antiseptic within the clinical setting and is the recommended antimicrobial within the 277 
EPIC and HICPAC guidelines.
11,12
 However, infection rates associated with surgical 278 
incision of the skin remain high.
4
 Thus the current strategies adopted for skin antisepsis 279 
need to be considered with a view for improvement. 280 
The antimicrobial activity of CHG alone in vivo is reported as being 281 
bacteriostatic
36
 and may be one factor which contributes to the survival of S. epidermidis 282 
within the skin following antisepsis and its association with subsequent infection. 283 
Furthermore, sub-inhibitory concentrations of chlorhexidine may increase a biofilm-mode 284 
of growth of staphylococci,
37
 which may reduce the efficacy of skin antisepsis if 285 
inappropriate levels of antiseptic are used. The synergistic action of CHG in combination 286 
with EO may therefore be one way forward for enhancing both skin antisepsis and 287 
potentially disinfection of hard surfaces. The environment in the healthcare setting 288 
contributes to the spread of pathogens and transfer of microorganisms between patients 289 
and healthcare workers.
38
 Microorganisms may reside on surfaces in aggregates 290 
embedded in a biofilm rendering them less susceptible to cleaning and disinfection. 291 
Furthermore, many medical devices such as central venous catheter hubs and needleless 292 
connectors also become colonised with microorganisms capable of producing a biofilm.
39
 293 
At present chlorhexidine-based compounds or isopropyl alcohol are commonly used for 294 
disinfecting these medical devices prior to use. The synergistic activity between CHG and 295 
EO in combination may therefore be of benefit in the clinical setting, for example, in 296 
improved skin antisepsis and the elimination of S.epidermidis existing as microcolonies 297 
which are likely to exhibit increased resistance to CHG alone, and also potentially hard 298 
surface disinfection. However, whilst much of the research data advocates the potential 299 
use of essential oils in the clinical setting for preventing and treating infection there is 300 
little information regarding safety in relation to their use, which needs to be taken into 301 
consideration. Therefore further studies are warranted. 302 
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Table 1. MIC and MBC of aqueous chlorhexidine digluconate, eucalyptus oil, tea tree oil and thymol against clinical TK1 and RP62A 461 
strains of S.epidermidis in suspension and in biofilm. 462 
 463 
Strain 
 
 
Compound MIC 
(g/ L for oils, mg/ L for CHG) 
MBC 
(g/ L for oils, mg/ L for CHG) 
Suspension Biofilm Suspension Biofilm 
RP62A Eucalyptus 4 32 64 256 
Tea tree oil 2 16 4 64 
Thymol 4 0.5 16 2 
CHG 2 8 4 16 
TK1 Eucalyptus 8 64 32 256 
Tea tree oil 16 16 64 32 
Thymol 0.5 0.5 4 8 
CHG 2 8 4 16 
464 
Table 2. Antimicrobial activity of aqueous chlorhexidine digluconate, eucalyptus oil, tea tree oil and thymol against clinical TK1 and 465 
RP62A strains of S.epidermidis growing in suspension. 466 
 467 
Strain 
 
 
 
Combination MIC of oil (g/L) in 
combination/ 
alone 
FIC of 
oil 
MIC of CHG(mg/L) 
in combination/ 
alone 
FIC of 
CHG 
FICI Result 
RP62A CHG + Eucalyptus 4 / 4 1 2/ 2 1 2 Indifference 
CHG + Tea tree oil 2 / 2 1 2/ 2 1 2 Indifference 
CHG + Thymol 1/ 4 0.25 2/ 2 1 1.25 Indifference 
TK1 CHG + Eucalyptus 8 / 8 1 2 / 2 1 2 Indifference 
CHG + Tea tree oil 16 / 16 1 2 / 2 1 2 Indifference 
CHG + Thymol 0.25 / 0.5 0.5 2 / 2 1 1.5 Indifference 
468 
Table 3. Antimicrobial activity of aqueous chlorhexidine digluconate, eucalyptus oil, tea tree oil and thymol against clinical TK1 and 469 
RP62A strains of S.epidermidis growing in biofilm. 470 
 471 
Strain 
 
 
 
Combination MIC of oil (g/L) in 
combination/ 
alone 
FIC of 
oil 
MIC of CHG(mg/L) 
in combination/ 
alone 
FIC of 
CHG 
FICI Result 
RP62A CHG + Eucalyptus  4 / 32 0.125 0.25/ 8 0.031 0.156 Synergy 
CHG + Tea tree oil 4 / 16 0.25 4/ 8 0.5 0.75 Indifference 
CHG + Thymol 0.5 / 0.5 1 8/ 8 1 2 Indifference 
TK1 CHG + Eucalyptus 4 / 64 0.063 1 / 8 0.125 0.188 Synergy 
CHG + Tea tree oil 16 / 16 1 8 / 8 1 2 Indifference 
CHG + Thymol 0.25 / 0.5 0.5 4 / 8 0.5 1 Indifference 
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